[1] 刘利容, 吴涛, 詹思延, 等. 利巴韦林的安全性和有效性-Meta分析结果的系统综述[J].药物不良反应杂志,2006,8(3):184-187. [2] Randolph A G, Wang E E. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview[J]. Archives of Pediatrics & Adolescent Medicine, 1996, 150(9):942. [3] 吴晔, 吴涛, 詹思延, 等. 利巴韦林的安全性与利益-风险分析[J].药物流行病学杂志,2006,15(4):210-213. [4] 杨秀萍, 魏文灵. 利巴韦林注射液致急性白细胞减少、溶血性贫血1例[J].中国药物警戒,2010,7(10):633-633. [5] 王菡茵, 曾睿. 左氧氟沙星、磷霉素钠和利巴韦林不合理使用致死亡1例[J].中国药物警戒,2011,8(12):764-766. [6] Yang Y, Zhou X, Gao S, et al. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China[J]. Drug Saf,2017, doi: 10.1007/s40264-017-0589-z. [7] Xiang Z, Gonzalez R, Ren L, et al. Prevalence and clinical characteristics of human respiratory syncytial virus in Chinese adults with acute respiratory tract infection[J]. Journal of Medical Virology, 2013, 85(2):348-53. [8] 吴婷, 吴涛, 詹思延, 等. 利巴韦林致癌、致畸和致突变作用的综合评价[J].药物不良反应杂志,2006,8(4):244-247. [9] Sinclair S M, Jones J K, Miller R K, et al. The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment[J]. Drug Saf, 2017, 40(12):1205-1218. [10] 谭芳. 基层医务人员对利巴韦林致畸认知度现状调查[J].大家健康(学术版),2013,7(8):3-4. |